论文部分内容阅读
29例可评估的复发性或对早期诱导治疗(阿糖胞苷,正定霉素±表鬼臼毒甲醛糖甙)无效的急非淋白血病(ANLL),使用ATA方案治疗100mg/M~2/天,静脉滴注×2～5天,每例使用1—6个疗程(中位数2),7例(24％)获完全缓解,缓解期分别2.2.2.5.9~+.19.24~+个月,以往缓解期超过6个月(6/13,46％)的病例,其完全缓解率显著高于(X~2=4.25,P<0.05)6个月以内复发或对早期诱导化疗无效的病例(1/16,6％),主要毒性反应为骨髓抑制,非血液系统的毒性反应很轻.
29 evaluable recurrent or acute non-leukemias (ANLL) refractory to early induction therapy (cytarabine, doxorubicin + etoposide), ATA regimen of 100 mg / M ~ 2 / Day and intravenous drip for 2 to 5 days, with 1-6 courses (median 2) in each case and complete remission in 7 cases (24%), with remission rates of 2.2.2.5.9 to +19.24 to + Months, the complete remission rate was significantly higher than that (X ~ 2 = 4.25, P <0.05) in 6 months (6/13, 46%) in previous remission or 6 months (1/16, 6%). The main toxicity was myelosuppression. The toxicity of non-hematological system was very mild.